title: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
abstract: The resistance of HIV clinical isolates with or without M184V was analysed in relation to plasma HIV-1-RNA level and time on therapy. The number of thymidine analogue mutations (TAMs) was lower in isolates with M184V, this was independent of plasma HIV-1-RNA level and time on therapy for T215F/Y, D67N and L210W. This suggests a direct effect of M184V on the reduced selection of TAMs. Lamivudine use was significantly associated with lower median fold resistance to zidovudine and stavudine.
authors.affiliation: International Clinical Virology Unit, UK.
authors.forename: Mounir
authors.initials: M
authors.lastname: Ait-Khaled
authors.forename: Chris
authors.initials: C
authors.lastname: Stone
authors.forename: Gillian
authors.initials: G
authors.lastname: Amphlett
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.forename: Schlomo
authors.initials: S
authors.lastname: Staszewski
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Margaret
authors.initials: M
authors.lastname: Tisdale
mesh_terms: D004352:Drug Resistance, Microbial / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D009154:Mutation; D010641:Phenotype; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D018119:Stavudine / Q000494:pharmacology* / Q000627:therapeutic use; D013936:Thymidine / Q000031:analogs & derivatives*; D019562:Viral Load; D015215:Zidovudine / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D018119:Stavudine; D013936:Thymidine